News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
604,447 Results
Type
Article (32353)
Company Profile (173)
Press Release (571910)
Multimedia
Podcasts (115)
Webinars (11)
Section
Business (168396)
Career Advice (1614)
Deals (30067)
Drug Delivery (114)
Drug Development (70880)
Employer Resources (88)
FDA (14627)
Job Trends (12597)
News (286776)
Policy (24420)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (3)
Academia (2243)
Academic (1)
Accelerated approval (28)
Adcomms (15)
Allergies (128)
Alliances (43705)
ALS (144)
Alzheimer's disease (1415)
Antibody-drug conjugate (ADC) (314)
Approvals (14952)
Artificial intelligence (540)
Autoimmune disease (140)
Automation (37)
Bankruptcy (249)
Best Places to Work (10292)
BIOSECURE Act (20)
Biosimilars (168)
Biotechnology (117)
Bladder cancer (153)
Brain cancer (53)
Breast cancer (637)
Cancer (4728)
Cardiovascular disease (381)
Career advice (1321)
Career pathing (26)
CAR-T (275)
CDC (28)
Celiac Disease (1)
Cell therapy (725)
Cervical cancer (35)
Clinical research (61443)
Collaboration (1711)
Company closure (2)
Compensation (964)
Complete response letters (48)
COVID-19 (2325)
CRISPR (94)
C-suite (754)
Cystic fibrosis (144)
Data (5985)
Decentralized trials (2)
Denatured (28)
Depression (117)
Diabetes (518)
Diagnostics (6486)
Digital health (46)
Diversity (9)
Diversity, equity & inclusion (18)
Drug discovery (241)
Drug pricing (141)
Drug shortages (28)
Duchenne muscular dystrophy (195)
Earnings (75006)
Editorial (43)
Employer branding (14)
Employer resources (80)
Events (93612)
Executive appointments (881)
FDA (17621)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (8)
Frontotemporal dementia (20)
Funding (1399)
Gene editing (199)
Generative AI (46)
Gene therapy (565)
GLP-1 (1102)
Government (3419)
Grass and pollen (5)
Guidances (375)
Healthcare (16205)
HIV (58)
Huntington's disease (40)
IgA nephropathy (82)
Immunology and inflammation (247)
Immuno-oncology (57)
Indications (103)
Infectious disease (2575)
Inflammatory bowel disease (184)
Inflation Reduction Act (13)
Influenza (110)
Intellectual property (226)
Interviews (281)
IPO (14909)
IRA (31)
Job creations (2694)
Job search strategy (1125)
JPM (57)
Kidney cancer (17)
Labor market (76)
Layoffs (438)
Leadership (29)
Legal (5153)
Liver cancer (89)
Longevity (12)
Lung cancer (639)
Lymphoma (359)
Machine learning (41)
Management (28)
Manufacturing (744)
MASH (162)
Medical device (13537)
Medtech (13590)
Mergers & acquisitions (16233)
Metabolic disorders (1337)
Multiple sclerosis (157)
NASH (18)
Neurodegenerative disease (291)
Neuropsychiatric disorders (81)
Neuroscience (2551)
Neurotech (1)
NextGen: Class of 2026 (5444)
Non-profit (3453)
Now hiring (34)
Obesity (649)
Opinion (207)
Ovarian cancer (161)
Pain (193)
Pancreatic cancer (218)
Parkinson's disease (264)
Partnered (30)
Patents (440)
Patient recruitment (457)
Peanut (55)
People (45849)
Pharmaceutical (35)
Pharmacy benefit managers (14)
Phase 1 (20699)
Phase 2 (26489)
Phase 3 (19748)
Pipeline (4976)
Policy (191)
Postmarket research (1927)
Preclinical (7683)
Press Release (69)
Prostate cancer (235)
Psychedelics (35)
Radiopharmaceuticals (269)
Rare diseases (768)
Real estate (4716)
Recruiting (40)
Regulatory (19806)
Reports (38)
Research institute (2120)
Resumes & cover letters (290)
Rett syndrome (27)
RNA editing (18)
RSV (70)
Schizophrenia (141)
Series A (240)
Series B (182)
Service/supplier (8)
Sickle cell disease (89)
Special edition (22)
Spinal muscular atrophy (162)
Sponsored (37)
Startups (3138)
State (2)
Stomach cancer (15)
Supply chain (99)
Tariffs (64)
The Weekly (85)
Vaccines (891)
Venture capital (72)
Weight loss (443)
Women's health (71)
Worklife (12)
Date
Last 7 days (566)
Last 30 days (1841)
Last 365 days (28535)
2026 (2648)
2025 (29008)
2024 (32733)
2023 (36635)
2022 (47006)
2021 (50359)
2020 (47721)
2019 (40113)
2018 (30454)
2017 (29170)
2016 (27023)
2015 (31617)
2014 (23646)
2013 (19419)
2012 (20743)
2011 (21307)
2010 (19449)
Location
Africa (637)
Alabama (86)
Alaska (6)
Arizona (239)
Arkansas (13)
Asia (37505)
Australia (6244)
California (10318)
Canada (3032)
China (1101)
Colorado (444)
Connecticut (454)
Delaware (318)
Europe (82998)
Florida (1552)
Georgia (320)
Hawaii (3)
Idaho (49)
Illinois (786)
India (62)
Indiana (478)
Iowa (17)
Japan (425)
Kansas (120)
Kentucky (39)
Louisiana (26)
Maine (59)
Maryland (1260)
Massachusetts (7530)
Michigan (332)
Minnesota (593)
Mississippi (6)
Missouri (131)
Montana (33)
Nebraska (19)
Nevada (118)
New Hampshire (85)
New Jersey (2834)
New Mexico (22)
New York (2707)
North Carolina (1357)
North Dakota (9)
Northern California (4946)
Ohio (289)
Oklahoma (20)
Oregon (41)
Pennsylvania (2013)
Puerto Rico (22)
Rhode Island (38)
South America (947)
South Carolina (60)
South Dakota (1)
Southern California (4127)
Tennessee (163)
Texas (1614)
United States (36882)
Utah (304)
Vermont (1)
Virginia (230)
Washington D.C. (61)
Washington State (849)
West Virginia (4)
Wisconsin (119)
Wyoming (2)
604,447 Results for "medisafe 1 technologies".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
Hydreight Technologies Issues Fiscal 2026 Revenue Guidance of ≈ $150 Million and Provides Q1 2026 Outlook
February 2, 2026
·
11 min read
Funding
China’s Corxel Nabs $287M Series D1 to Bankroll GLP-1 Pill
Corxel will use the fundraising proceeds to advance the oral GLP-1 therapy CX11 through mid-stage development in the U.S., as well as prepare for its Phase III studies.
January 23, 2026
·
1 min read
·
Tristan Manalac
Press Releases
Archeus Technologies Doses First Patient with ART-101 in Phase 1 Prostate Cancer Study
December 3, 2025
·
4 min read
Cell therapy
After Cell Therapy Retreat, Novo Offloads Technologies in Deepened Aspect Pact
Novo Nordisk pulled back from cell therapies last October, scrapping development of a type 1 diabetes therapy and laying off most employees working on this modality.
January 21, 2026
·
2 min read
·
Tristan Manalac
Earnings
GSK Says No to GLP-1s, Prioritizes ‘Downstream Effects’ of Obesity
Instead of joining the increasingly crowded GLP-1 arena, GSK will focus its efforts downstream of obesity—a push currently anchored by its Phase III-ready FGF21 analog efimosfermin alfa for liver fibrosis.
February 4, 2026
·
2 min read
·
Tristan Manalac
pipeline
Lilly Axes 3 Therapies Amid Pipeline-in-a-Product Push for GLP-1
One of the assets shelved by Eli Lilly is a gene therapy for dementia, which it obtained in its $1.04-billion acquisition of Prevail Therapeutics in late 2020.
February 5, 2026
·
2 min read
·
Tristan Manalac
Collaboration
GSK Joins Growing PD-1 SubQ Push With Alteogen Alliance Worth up to $285M+
Ahead of GSK are Bristol Myers Squibb and Merck, which have already won FDA approvals for subcutaneous formulations of their respective PD-1 blockers Opdivo and Keytruda.
January 21, 2026
·
1 min read
·
Tristan Manalac
Inflammatory bowel disease
Boehringer Commits up to $1.26B in IBD Pact With China’s Simcere
The cornerstone of the deal is SIM0709, which Simcere designed to target both TL1A and IL-23, crucial players in facilitating inflammation. Boehringer Ingelheim will advance the asset for inflammatory bowel diseases.
January 27, 2026
·
2 min read
·
Tristan Manalac
Obesity
AstraZeneca’s China Trip Yields CSPC Obesity Deal Worth $1.2B Upfront
The pact, which could see AstraZeneca ultimately put out $18.5 billion in milestones and sales-based payments, is centered on SYH2082, a long-acting dual agonist of the GLP-1 and GIP receptors.
January 30, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
Lilly Eyes Pipeline in a Product as GLP-1s Move Into I&I
In addition to claiming revenue of $19.3 billion for the fourth quarter, Eli Lilly executives offered a glimpse into their strategy to expand their GLP-1 franchise into the immunology and inflammation space, with trials currently underway in asthma, psoriatic arthritis, Crohn’s disease and ulcerative colitis.
February 4, 2026
·
2 min read
·
Heather McKenzie
1 of 60,445
Next
